|
🐜
|
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
30 auth.
I. Ray-Coquard,
P. Pautier,
S. Pignata,
D. Pérol,
A. González-Martín,
R. Berger,
K. Fujiwara,
I. Vergote,
N. Colombo,
J. Mäenpää,
F. Selle,
J. Sehouli,
D. Lorusso,
E. G. Guerra Alía,
A. Reinthaller,
...
S. Nagao,
C. Lefeuvre-Plesse,
U. Canzler,
G. Scambia,
A. Lortholary,
F. Marmé,
P. Combe,
N. de Gregorio,
M. Rodrigues,
P. Buderath,
C. Dubot,
A. Burges,
B. You,
E. Pujade-Lauraine,
P. Harter
|
10 |
2019 |
10
🐜
|
|
🐜
|
Survival with Cemiplimab in Recurrent Cervical Cancer.
35 auth.
K. Tewari,
B. Monk,
I. Vergote,
A. Miller,
A. D. de Melo,
H. Kim,
Y. M. Kim,
A. Lisyanskaya,
V. Samouëlian,
D. Lorusso,
F. Damian,
Chih-Long Chang,
Evgeniy Gotovkin,
S. Takahashi,
D. Ramone,
...
J. Pikiel,
B. Maćkowiak-Matejczyk,
E. G. Guerra Alía,
N. Colombo,
Y. Makarova,
D. Rischin,
S. Lheureux,
K. Hasegawa,
K. Fujiwara,
Jingjin Li,
Shaheda Jamil,
V. Janković,
Chieh-I. Chen,
F. Seebach,
D. Weinreich,
G. Yancopoulos,
I. Lowy,
M. Mathias,
M. Fury,
A. Oaknin
|
7 |
2022 |
7
🐜
|
|
🐜
|
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
20 auth.
Philipp Harter,
M. Mouret-Reynier,
S. Pignata,
C. Cropet,
Antonio González-Martín,
Gerhard Bogner,
Keiichi Fujiwara,
I. Vergote,
N. Colombo,
T. Nøttrup,
...
A. Floquet,
A. El-Balat,
G. Scambia,
E. G. Guerra Alía,
Michel Fabbro,
Barbara Schmalfeldt,
A. Hardy-Bessard,
Ingo B. Runnebaum,
E. Pujade-Lauraine,
I. Ray-Coquard
|
5 |
2021 |
5
🐜
|
|
🐜
|
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
21 auth.
V. Makker,
N. Colombo,
A. C. Herráez,
B. Monk,
H. MacKay,
A. Santin,
D. Miller,
R. Moore,
S. Baron-Hay,
I. Ray-Coquard,
...
K. Ushijima,
K. Yonemori,
Yong Man Kim,
E. G. Guerra Alía,
U. Sanli,
Steven Bird,
R. Orlowski,
J. McKenzie,
C. Okpara,
G. Barresi,
D. Lorusso
|
5 |
2023 |
5
🐜
|
|
🐜
|
Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.
20 auth.
R. Sabatier,
F. Rousseau,
F. Joly,
C. Cropet,
C. Montégut,
J. Frindte,
S. Cinieri,
E. G. Guerra Alía,
S. Polterauer,
H. Yoshida,
...
I. Vergote,
N. Colombo,
S. Hietanen,
Rémi Largillier,
U. Canzler,
A. Gratet,
F. Marmé,
L. Favier,
E. Pujade-Lauraine,
I. Ray-Coquard
|
3 |
2022 |
3
🐜
|
|
🐜
|
2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775
20 auth.
Domenica Lorusso,
V. Makker,
A. C. Herráez,
B. Monk,
H. Mackay,
Alessandro D Santin,
David S Miller,
R. Moore,
S. Baron-Hay,
I. Ray-Coquard,
...
R. Shapira-Frommer,
Kimio Ushijima,
K. Yonemori,
Yong Man Kim,
E. G. Guerra Alía,
U.A. Sanli,
Jie Huang,
J. McKenzie,
G. Barresi,
N. Colombo
|
2 |
2022 |
2
🐜
|
|
🦁
|
Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
E. G. Guerra Alía,
Cayetano Sempere Ortega,
A. Cortés Salgado,
C. Sanchez Martínez,
J. Galindo Álvarez,
Belén Pérez Miez
|
1 |
2019 |
1
🦁
|
|
🐜
|
525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775
20 auth.
V. Makker,
N. Colombo,
A. Casado Herráez,
B. Monk,
H. Mackay,
A. Santin,
D. Miller,
R.G. Moore,
S. Baron-Hay,
I. Ray-Coquard,
...
R. Shapira-Frommer,
K. Ushijima,
K. Yonemori,
Y. Kim,
E. G. Guerra Alía,
U. Sanli,
J. Huang,
J. McKenzie,
G. Barresi,
D. Lorusso
|
1 |
2022 |
1
🐜
|
|
🐜
|
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
36 auth.
Antonio González-Martín,
M. J. Rubio,
F. Heitz,
René Depont Christensen,
N. Colombo,
T. van Gorp,
M. Romeo,
I. Ray-Coquard,
L. Gaba,
A. Leary,
L. D. de Sande,
C. Lebreton,
A. Redondo,
Michel Fabbro,
M. Barretina Ginesta,
...
Philippe Follana,
J. Pérez-Fidalgo,
M. Rodrigues,
A. Santaballa,
Renaud Sabatier,
M.J. Bermejo-Pérez,
J. Lotz,
Beatriz Pardo,
Gloria Marquina,
L. Sánchez-Lorenzo,
M. Quindós,
P. Estévez-García,
E. G. Guerra Alía,
Luis Manso,
Victoria Casado,
Stefan Kommoss,
G. Tognon,
Stéphanie Henry,
I. Bruchim,
A. Oaknin,
Frédéric Selle
|
1 |
2024 |
1
🐜
|
|
🐜
|
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma
32 auth.
L. Verlingue,
Antoine Italiano,
H. Prenen,
E. G. Guerra Alía,
D. Tosi,
Ruth Perets,
I. Lugowska,
V. Moiseyenko,
M. Gumus,
Cagatay Arslan,
Colin R Lindsay,
Sanjeev Deva,
Á. Taus,
A. Oaknin,
Sylvie Rottey,
...
Irfan Cicin,
S. Goksu,
A. Smolin,
Susana Roselló-Keränen,
Christin Habigt,
Daniel Marbach,
C. Boetsch,
D. Dejardin,
Nassim Sleiman,
Stefan Evers,
Muriel Richard,
Caroline Ardeshir,
Jehad Charo,
A. Kraxner,
Volker Teichgräber,
N. Keshelava,
R. Dziadziuszko
|
1 |
2024 |
1
🐜
|
